There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MAIA Biotechnology, Inc. (MAIA – Research Report) and Becton Dickinson (BDX – Research Report) with bullish sentiments.
MAIA Biotechnology, Inc. (MAIA)
Noble Financial analyst Robert LeBoyer maintained a Buy rating on MAIA Biotechnology, Inc. today and set a price target of $14.00. The company’s shares closed last Tuesday at $2.10, close to its 52-week low of $2.02.
According to TipRanks.com, LeBoyer is ranked 0 out of 5 stars with an average return of
MAIA Biotechnology, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $14.00.
See Insiders’ Hot Stocks on TipRanks >>
Becton Dickinson (BDX)
In a report released today, Travis Steed from Bank of America Securities reiterated a Buy rating on Becton Dickinson, with a price target of $305.00. The company’s shares closed last Tuesday at $281.10, close to its 52-week high of $287.32.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Becton Dickinson with a $307.44 average price target, which is an 11.3% upside from current levels. In a report issued on August 4, Morgan Stanley also maintained a Buy rating on the stock with a $310.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MAIA:
